12:00 AM
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Incivek: Additional Phase II data

Additional data from 60 evaluable HCV patients co-infected with HIV-1 from both parts of a 2-part, double-blind, international Phase II trial showed that 74% of patients receiving oral Incivek plus standard of care (SOC; peginterferon alfa-2a and ribavirin) achieved an SVR defined as undetectable HCV RNA levels 12 weeks after the end of treatment (SVR12), a secondary endpoint, vs. 45% for placebo plus SOC. Part A of the trial is evaluating Incivek in patients not currently being treated with antiretroviral therapy for HIV infection, while Part B is evaluating Incivek in patients receiving Atripla efavirenz/tenofovir/emtricitabine or a Reyataz atazanavir-based regimen for HIV. In Part A, the SVR12 rate was 71% for patients receiving Incivek plus SOC vs. 33% for placebo plus...

Read the full 601 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >